Form 4: Lantern Pharma Director Granted Stock Options

Lantern Pharma Inc. Director David S. Silberstein was granted 42,307 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Summary

• David S. Silberstein, a Director of Lantern Pharma Inc. (LTRN), was granted stock options on January 9, 2026.
• The options were granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.
• A total of 25,000 stock options were granted with an exercise price of $3.49, vesting in equal monthly increments over a 24-month period commencing February 9, 2026.
• An additional 17,307 stock options were granted with an exercise price of $3.49, vesting in equal monthly increments over a 12-month period commencing February 9, 2026.
• Both sets of options have an expiration date of January 8, 2036.
• Following these transactions, David S. Silberstein beneficially owns 25,000 and 17,307 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The options are granted under an established and amended stock incentive plan, indicating a structured approach to executive and director compensation.

Future Outlook

The vesting schedules for the granted stock options, commencing February 9, 2026, over 12 and 24 months, indicate a forward-looking incentive structure designed to retain and motivate the director over the medium term.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, particularly for companies like Lantern Pharma Inc. which are often in development stages. This compensation method is used to align the interests of leadership with long-term shareholder value creation, given the typically long development cycles and regulatory hurdles in the sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director is intended to align the director's financial interests with long-term shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: While this specific filing is for a director, the existence and use of a stock incentive plan can positively influence overall employee morale and retention if similar opportunities are available to other key personnel.

Next Steps

• The granted stock options will begin vesting in equal monthly increments starting February 9, 2026, over periods of 12 and 24 months.

Key Dates

Keywords

LTRN, Lantern Pharma, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Incentive Plan